Contact for more Information
Technology Alerts minus

Sign up to receive TIDO’s monthly newsletter highlighting new Children’s Hospital technologies and research and development partnership opportunities.

sign me up
Related Informationminus

Lodamin for the Treatment of Cancer

Originally identified in the late Dr.

send to a friend

CMCC 1810

Lodamin for Treating Eye Diseases

Inventors: Robert D'Amato, Ofra Benny-Ratsaby, Kei Nakai

Categories: Therapeutics

SubCategories: Ophthalmology

Keywords: Anti-angiogenesis

Invention Description:

Lodamin is a novel anti-angiogenic drug and a non-toxic derivative of TNP-470. The anti-angiogenic activity of Lodamin was demonstrated in different tumor models in mice. Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are well known angiogenesis-dependent eye diseases for which there remains an unmet medical need. Drs. Benny and D'Amato have found in the mouse corneal micropocket assay and in the mouse laser-induced choroidal neovascularization (CNV) assay that Lodamin inhibited corneal neovascularization, CNV lesion size (by 71% when administered orally), and ocular vessel permeability.


The discovery by Drs. Benny and D'Amato indicate that Lodamin may be a novel therapy for ocular neovascular diseases, such as AMD and DR. Both of these diseases are leading causes of vision loss and blindness in both developed and developing nations. There are approximately 2 million AMD patients in the US, and up to 45 percent of adults diagnosed with diabetes in the US have some degree of diabetic retinopathy. In addition to retinal neovascular diseases, Lodamin could also treat corneal neovascular diseases.

Competitive Advantages:

The only treatment options for DR are surgical interventions, and there is no cure for AMD. Presently approved anti-angiogenic therapies for AMD are biological agents such as an anti-VEGF aptamer (Macugen) and a Fab fragment of a monoclonal antibody directed against VEGF-A (Lucentis). Lodamin is an oral and broad acting anti-angiogenic agent. There is currently no approved direct anti-angiogenic drug for corneal vascularization diseases and this may be an advantageous regulatory path for Lodamin. Visual loss in AMD and corneal vascular disease are due to both vessel growth and leakage of fluid. Contrary to available treatments at this time, Lodamin is able to inhibit both of these mechanisms. Taken together, we believe Lodamin has superior properties that enable it to compete with products available in the eye disease market today.

Business Opportunity:

Exclusive license available

Key Publications: Benny O et al., PLoS One, 2010 Sep 1; 5(9), pii: e12515.

IPStatus: Pat. Pend.

Terms and Conditions children's hospital
Site Designed and Developed by Genuine